Fady I. Malik

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

John R. Teerlink, Rafael Díaz, G. Michael Felker et al. · New England Journal of Medicine · 2020 · 625 citations · Full text

Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure

Fady I. Malik, James J. Hartman, Kathleen A. Elias et al. · Science · 2011 · 590 citations · Full text

Cardiac Muscle, Heart Failure, Cardiovascular Pharmacology +20

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 329 citations

Cardiomyopathy, Heart Failure, Omecamtiv Mecarbil +10

Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

John R. Teerlink, G. Michael Felker, John J.V. McMurray et al. · The Lancet · 2016 · 287 citations · Full text

Cardiac Muscle, Cardiomyopathy, Heart Failure +10

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali et al. · The Lancet · 2011 · 260 citations

Cardiac Muscle, Cardiomyopathy, Omecamtiv Mecarbil +12